Novel Pharmacological Targets for Calcific Aortic Valve Disease: Prevention and Treatments

Le più recenti evidenze di letteratura sui possibili target terapeutici per questa condizione debilitante e fatale. (Pharmacol Res 2018 Aug 24;136:74-82)

6 Settembre Set 2018 3 months ago
  • Myasoedova VA, Ravani AL, Frigerio B, Valerio V, Moschetta D, Songia P, Poggio P.

Calcific aortic valve disease (CAVD) is the most common valvular disorder in the elderly, with the incidence of 3% in general population of Western countries. The initial phase of CAVD is characterized by leaflet thickening and possible spotty calcification (i.e. aortic valve sclerosis (AVSc)), while advanced stages have leaflets structure degeneration (i.e. aortic valve stenosis (AS)).

The pathological cellular and molecular mechanisms, involved in CAVD, are extracellular matrix degradation, aberrant matrix deposition, fibrosis, mineralization, inflammation, lipid accumulation, and neo-angiogenesis. CAVD clinical risk shares considerable overlap with those of atherosclerosis and they include hypertension, smoking habits, and hyperlipidemia. Unfortunately, surgical aortic valve replacement and transcatheter aortic valve implantation are the only available treatments when the disease become severe and symptoms occur. Indeed, no approved pharmacological approach is available for CAVD patients.

In this review, the Authors describe the current literature evidence on possible future therapeutic targets for this debilitating and fatal disease such as PCSK9, P2Y2 receptor, cadherin 11, and DDP-4.

Reference
1. Myasoedova VA, Ravani AL, Frigerio B, Valerio V, Moschetta D, Songia P, Poggio P. Novel Pharmacological Targets for Calcific Aortic Valve Disease: Prevention and Treatments. Pharmacol Res 2018 Aug 24;136:74-82. Go to PubMed